This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Dev

Abivax CEO highlights pipeline assets, including lead HIV drug

Posted by on 15 November 2017
Share this article

Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for its lead clinical-stage molecule against HIV. Abivax is developing one of the first compounds, ABX464, to demonstrate an effect on human immunodeficiency (HIV) reservoirs in Phase II clinical trials. It is a first-in-class oral small anti-viral molecule, which blocks HIV replication through a unique mechanism of action. The French company is also developing ABX464 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. A clinical study for the drug in IBD is currently enrolling patients.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down